Flavonoids Targeting the mTOR Signaling Cascades in Cancer: A Potential Crosstalk in Anti-Breast Cancer Therapy

Table 1

mTOR inhibitors used in clinical trials for the management of different breast cancers.

Drugs/compounds	Study design	Nature of breast cancer	References
Fulvestrant+everolimus	Phase II clinical trials	Positive breast cancer (estrogen receptor)	[31]
Everolimus	Retrospective	Metastatic breast cancer	[32]
Exemestane+everolimus	Phase III (randomized trial)	Advanced breast cancer (hormone-receptor-positive)	[33]
Temsirolimus	Phase II	Metastatic breast cancer	[34]
Tamoxifen+everolimus	Phase II (randomized trial)	Metastatic breast cancer	[35]
Tamoxifen+sirolimus	Phase I and phase II	HER2-negative breast cancer and hormone receptor-positive	[36]
Plustrastuzumab+vinorelbine+everolimus	Phase III	HER2-positive breast cancer	[37]
Trastuzumab+ridaforolimus	Phase IIb	Trastuzumab-refractory metastatic breast cancer (human epidermal growth factor receptor 2–positive)	[38]
Paclitaxel+trastuzumab+everolimus	Phase II	Advanced breast cancer (HER-2 positive)	[39]
Letrozole+temsirolimus	Phase III randomized	Metastatic breast cancer (hormone receptor-positive)	[40]